Big Pharma's $170 Billion Patent Cliff Triggers the Biggest M&A Race in Decades
As Keytruda, Eliquis, and Ozempic approach patent expiration, pharmaceutical giants are racing to acquire biotech assets in what analysts call a once-in-a-generation opportunity.